Skip to main content

Table 1 Patient characteristic at baseline

From: A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis

 

Patients (N = 8)

Age, median (range), years

55 (30–65)

Histology, N (%)

 

 Invasive ductal carcinoma

6 (75%)

 Invasive lobular carcinoma

1 (13%)

 Unknown

1 (13%)

Hormone receptor status, N (%)

 

 ER+ and PR+

3 (38%)

 ER- and PR-

5 (63%)

HER2 expression, N (%)

 

 IHC 0-2+ and/or FISH-

3 (38%)

 IHC 2+ and FISH+, IHC3+

2 (25%)

Triple negative, N (%)

 

 Yes

3 (38%)

 No

5 (63%)

ECOG performance status, N (%)

 

 <2

0 (0%)

 2

4 (50%)

 3

4 (50%)

Chemotherapy lines in metastatic setting, N (%)

 

 0

1 (13%)

 1

2 (25%)

 2

2 (25%)

3

3 (38%)

Coexisting brain parenchymal metastasis, N (%)

 

 Yes

7 (88%)

 No

1 (13%)

Prior therapy for CNS metastasis, N (%)

 

 Surgery

2 (25%)

 Radiotherapy

4 (50%)

Numbers of metastatic sites, N (%)

 

 Median (range)

2 (1–4)

 1

2 (25%)

 2

4 (50%)

 3

1 (13%)

 4

1 (13%)

Metastatic sites other than brain, N (%)

 

 Lung

3 (38%)

 Bone

2 (25%)

 Liver

1 (13%)

 Others

4 (50%)

Systemic disease not under control, N (%)

5 (63%)